Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
TIOBE Index for March 2026: Top 10 Most Popular Programming Languages Your email has been sent Python keeps the top spot as its rating dips again, C climbs further in second, and the bottom stays ...
Springer Nature is a signatory of the San Francisco Declaration on Research Assessment (DORA). Because small numbers of highly cited articles can have outsized influence on certain citation measures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results